CONDOR (CRTH258d2301) A 96-week, two-arm, randomized, single-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation lase in patients with proliferative diabetic retinopathy. 

KITE (CRTH258B2302) A two-year, two-arm, randomized, double-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to diabetic macular edema

KESTREL (CRTH258B2301) A two-year, three-arm, randomized, double-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to diabetic macular edema

LIGHTSITE II (CSP003) A double masked, randomized, sham-controlled, parallel group, multi-center study to assess the safety and efficacy of photobiomodulation (PBM) in subjects with dry age-related macular degeneration (AMD) 

RAPTOR (CRTH258C2301) An eighteen-month, two-arm, randomized, double-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to macular edema secondary to branch retinal vein occlusion

RAVEN (CRTH258C2302) An eighteen-month, two-arm, randomized, double-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to macular edema secondary to central retinal vein occlusion

TALON-EXTENSION (CRTH258A2303E1) A 56-week, phase IIIb/IV, open-label, one-arm extension study to assess the efficacy and safety of brolucizumab 6 mg in a Treat-to-Control regimen with maximum treatment intervals up to 20 weeks for the treatment of patients with neovascular age-related macular degeneration who have completed the CRTH258A2303 (TALON) study

TOLERANT STUDY A phase IV randomised, controlled study investigating the efficacy and safety of aflibercept “Treat and Extend” using a strict retreatment regimen compared to a relaxed retreatment regimen in patients with exudative age-related macular degeneration (AMD)